#Dyslipidemia

[trungtamthuocdantoc]

Trung tâm Thuốc Dân Tộc phối hợp với Viện Y Dược Dân Tộc Tradimex đã tổ chức thành công chương trình tuyên truyền và thăm khám xét nghiệm mỡ máu tại phường Xuân Đỉnh, quận Bắc Từ Liêm, Hà Nội. Hoạt động này nằm trong chuỗi chương trình chăm sóc sức khỏe cộng đồng với chủ đề: “Bảo Vệ Tim Mạch – Phòng Chống Đột Quỵ” nhằm nâng cao nhận thức cho người dân về cách phòng ngừa các bệnh lý nguy hiểm như đột quỵ và nhồi máu cơ tim thông qua kiểm soát mỡ máu.

[mikesparow1]

Emerging Developments In NASH Treatment

lifesciences review :Non-alcoholic steatohepatitis (NASH) is a progressive liver disease caused by inflammation, buildup of fat in the liver, and damage to liver cells. It is a more severe form of non-alcoholic fatty liver disease (NAFLD) and can lead to cirrhosis, liver failure, and liver cancer. NASH has become a growing global health concern due to its association with metabolic conditions like obesity, type 2 diabetes, and dyslipidemia. Currently, no approved therapies specifically target NASH, but several treatment approaches focus on managing its underlying risk factors and slowing disease progression. These include lifestyle interventions, off-label use of medications, and management of associated metabolic conditions.

[cardiologistdrfarhanshikoh]

डिसलिपिडेमिया: आपके दिल की सेहत के लिए महत्वपूर्ण जानकारी

डिसलिपिडेमिया एक स्थिति है जिसमें खून में लिपिड्स (वसा) का स्तर असामान्य होता है। ये लिपिड्स कोलेस्ट्रॉल और ट्राइग्लिसराइड्स होते हैं, जो कोशिकाओं ��े निर्माण और हार्मोन उत्पादन के लिए आवश्यक होते हैं। लेकिन इनका असंतुलन हृदय रोग और स्ट्रोक जैसी गंभीर स्वास्थ्य समस्याओं का कारण बन सकता है।

डिसलिपिडेमिया के सामान्य कारणों में आनुवंशिक कारक, खराब आहार, शारीरिक गतिविधि की कमी, मोटापा और कुछ चिकित्सीय स्थितियाँ शामिल हैं। इसके लक्षण अक्सर तब तक ध्यान में नहीं आते जब तक जटिलताएँ नहीं हो जातीं, इसलिए नियमित चेक-अप बहुत महत्वपूर्ण है।

डिसलिपिडेमिया का प्रबंधन जीवनशैली में बदलाव जैसे हृदय-स्वस्थ आहार अपनाना, नियमित व्यायाम करना, धूम्रपान छोड़ना और कभी-कभी चिकित्सकीय निर्देशानुसार दवाएँ लेना शामिल है।

हृदय से संबंधित समस्याओं के लिए व्यक्तिगत सलाह और संपूर्ण देखभाल के लिए, आप Dr. Md. Farhan Shikoh, MBBS, MD (Medicine), DM (Cardiology) से संपर्क कर सकते हैं। उनका पता है: सुकून हार्ट केयर, सैनिक मार्केट, मेन रोड, रांची, झारखंड: 834001। फोन: 6200784486। अपॉइंटमेंट बुक करने के लिए उनकी वेबसाइट drfarhancardiologist.com पर जाएँ।

[puppycap]

ND Health.AI — Your Destination for Diabetes Reversal and Dyslipidemia Treatment

Discover effective solutions for diabetes reversal and dyslipidemia treatment naturally at ND Health.AI. Our personalized programs cater to type 2 diabetes reversal, pre-diabetes prevention, and PCOD/PCOS management. Take charge of your health today!

Welcome to ND Health.AI: Your Premier Destination for Holistic Health Solutions

At ND Health.AI, we understand the pressing need for effective, natural solutions to prevalent health concerns like diabetes reversal naturally dyslipidemia, and PCOD PCOS. Our comprehensive approach combines cutting-edge AI technology with holistic health principles to provide personalized programs tailored to your unique needs.

Our Featured Programs:

Diabetes Reversal Program:Explore our innovative diabetes reversal program designed to help you regain control of your health. With a focus on natural methods and lifestyle modifications, our program empowers you to manage and potentially reverse type 2 diabetes.

2.Dyslipidemia Treatment:Combat dyslipidemia effectively with our evidence-based treatment protocols. Our approach targets underlying causes and focuses on lifestyle adjustments, dietary modifications, and supplementation to optimize lipid levels.

3.PCOD/PCOS Management:Find relief from PCOD/PCOS symptoms with our specialized management program. Our holistic approach addresses hormonal imbalances, insulin resistance, and lifestyle factors to promote hormonal harmony and overall well-being.

Why Choose ND Health.AI?

Personalized Approach: Our programs are tailored to your specific health profile and goals, ensuring optimal outcomes.

Evidence-Based Solutions: Backed by scientific research and clinical expertise, our interventions are proven to deliver results.

Supportive Community: Join a supportive community of individuals on a similar health journey, and benefit from shared experiences and encouragement.

Cutting-Edge Technology: Leveraging AI technology, we continuously refine and enhance our programs to deliver the most effective solutions.

Take the first step towards a healthier, happier you with ND Health.AI. Explore our website to learn more about our programs, meet our team of experts, and embark on your journey to optimal health today.

For more information:

[medicomunicare]

Clinical nutrition: minerals, vitamins and other natural bioactives to treat current medical issues

Introduction Vitamins and trace elements, collectively known as micronutrients, are vital for basic metabolic reactions in the human body. The deficiency of micronutrients or even increased amounts could lead to serious health disorders. Research has revealed that long-term abnormal levels of micronutrients could be associated with the etiopathogenesis of some common neurological diseases.…

[glutenfreedragonpotion]

I'm sooo dickslexsick

[funsimplethings]

[medscribr]

Tackling Lifestyle Disorders

I am writing this blog, because I keep getting queries about what can I do to have a healthy lifestyle or it runs in my family, is there anything I can do to prevent it and also to keep my promise of telling you more about what you can do take control of your health. In my last article ‘worrying about diseases running in your family’, I had told about how you can take control of the disease…

[trungtamthuocdantoc]

Đại diện Ban lãnh đạo Trung tâm Thuốc dân tộc và một số chuyên gia, bác sĩ đầu ngành tại đơn vị đã tham gia lễ ký quyết định thành lập dự án “Bảo vệ Tim mạch Việt Nam”. Đồng thời chính thức thành lập Hội đồng nghiên cứu bài thuốc đặc trị rối loạn lipid máu bằng YHCT.

[nirvananaturopathy]

Embark on a natural journey to lower cholesterol with Nirvana Naturopathy's holistic approach. Our naturopathy treatment for dyslipidemia offers effective and sustainable solutions. Visit Nirvana Naturopathy to start your path to healthier living today!

[marketsizereports]

Global Dyslipidemia Epidemiology Analysis: A Comparative Analysis of Regions and Countries

A comparative analysis of dyslipidemia epidemiology across regions and countries reveals variations in prevalence, risk factors, and healthcare approaches. Dyslipidemia, characterized by abnormal lipid levels in the bloodstream, is a global health concern with diverse impacts.

For more age insights into the Dyslipidemia market, download a free report sample

Regional and Country Variations:

North America:

United States: High prevalence of dyslipidemia due to factors like a diet rich in processed foods and sedentary lifestyles. Extensive healthcare infrastructure and emphasis on medication-based management.

Canada: Lower prevalence compared to the U.S., with a focus on lifestyle modifications, including healthy eating and physical activity.

Europe:

Western Europe: Higher prevalence in countries with affluent lifestyles and diets rich in saturated fats. Comprehensive healthcare systems support both medication and lifestyle interventions.

Eastern Europe: Lower but increasing prevalence with transitioning lifestyles and dietary habits. Access to healthcare varies across countries.

Asia:

China and India: Rising prevalence driven by rapid urbanization and dietary shifts. Varied healthcare infrastructure with a focus on early detection and lifestyle interventions.

Japan: Lower prevalence due to traditional dietary patterns and active lifestyles. Emphasis on maintaining these practices.

Middle East and North Africa (MENA):

Gulf Countries: High prevalence attributed to affluence, sedentary lifestyles, and high consumption of fast food. Extensive healthcare services with medication-focused interventions.

North Africa: Lower prevalence with varying healthcare access. A growing focus on public health measures and lifestyle interventions.

Sub-Saharan Africa:

South Africa: Rising prevalence due to urbanization and dietary shifts. Healthcare systems vary, with some countries emphasizing preventive strategies.

Other Sub-Saharan Countries: Generally lower prevalence, but access to healthcare services varies widely.

Latin America:

Brazil and Mexico: Increasing prevalence associated with urbanization and dietary changes. Varied healthcare access and strategies for managing dyslipidemia.

Other Latin American Countries: Lower prevalence, with an emerging focus on lifestyle interventions and dietary improvements.

Factors Influencing Variations:

Dietary Patterns: The consumption of saturated fats, trans fats, and processed foods significantly impacts dyslipidemia prevalence.

Lifestyle Choices: Physical inactivity, smoking, and excessive alcohol consumption contribute to the development of dyslipidemia.

Genetics: Genetic factors can predispose individuals to dyslipidemia, leading to variations in prevalence.

Healthcare Infrastructure: Access to healthcare services and the availability of medications influence management strategies.

Public Health Policies: Government policies related to public health, nutrition, and physical activity play a role in tackling dyslipidemia.

Awareness and Education: The level of awareness and education regarding dyslipidemia and its risk factors varies across regions, affecting preventive efforts.

Global Trends:

Prevention Focus: Increasing emphasis on preventive measures, including dietary improvements and lifestyle changes.

Pharmacotherapy: Medications, particularly statins, are widely used to manage dyslipidemia, although approaches may differ.

Telehealth: The adoption of telehealth services has expanded access to healthcare and monitoring, especially in remote or underserved regions.

Research and Innovation: Ongoing research and development efforts aim to improve pharmacological treatments and diagnostics for dyslipidemia.

In summary, dyslipidemia epidemiology varies significantly across regions and countries due to a combination of genetic, lifestyle, and healthcare system factors. While prevalence is influenced by diet and lifestyle, healthcare infrastructure, public health policies, and awareness efforts also play a crucial role in managing dyslipidemia on a global scale. The growing focus on prevention and the adoption of innovative healthcare solutions reflect the evolving landscape of dyslipidemia management.

[covid-safer-hotties]

Also preserved in our archive

By Dr. Sushama R. Chaphalkar, PhD.

In a recent research paper posted to the bioRxiv preprint* server, researchers in the United States investigated the potential effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on cholesterol metabolism, focusing on the role of the viral protein open reading frame 3a (ORF3a).

They found that SARS-CoV-2 causes cholesterol sequestration in lysosomes via the ORF3a protein, which disrupts protein trafficking and reduces the levels of bis(monoacylglycero)phosphate (BMP) in the cell, enhancing viral survival.

Background Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, disrupts lipid metabolism, particularly cholesterol homeostasis, which can persist during and after infection. This is linked to disease severity and long-term complications like dyslipidemia and cardiovascular diseases.

Cholesterol is crucial for cellular function and is primarily transported through lysosomes, where proteins like Niemann-Pick C1 and C2 (NPC1 and NPC2) facilitate its release. SARS-CoV-2 may exploit plasma membrane cholesterol to enhance infectivity.

Disruptions in the lysosomal cholesterol pathway can cause cholesterol buildup, impairing cellular functions, and viruses like Ebola are known to hijack this mechanism. Notably, BMP plays a dual role: it aids in cholesterol transport and contributes to viral infection by promoting viral fusion with lysosomal membranes.

In the present study, researchers investigated the potential impact of SARS-CoV-2 infection on cholesterol transport in cells, focusing on the role of the viral protein ORF3a.

About the Study A variety of experimental techniques were employed, including culturing A549, HeLa, and Vero E6 cells, followed by SARS-CoV-2 infection at different multiplicities of infection. SARS-CoV-2 ORF3a-VPS39 interaction was studied using mutations at key residues (notably W193 and Y184, which were identified as critical for this interaction). Immunofluorescence, filipin staining, and confocal microscopy were used to assess cholesterol localization and vesicular dynamics, while high-content imaging quantified cell-specific responses.

Cholesterol levels were measured using gas chromatography-mass spectrometry (GC-MS), and lipid species were analyzed through shotgun lipidomics. For further protein analysis, western blotting was performed to detect secreted NPC2 and cathepsin D, along with cell lysates. Data were analyzed using ImageJ and Prism 9, and statistical significance was determined by t-tests or analysis of variance.

Results and Discussion SARS-CoV-2 infection was found to increase filipin-positive puncta in lysosomes of A549-hACE2 and Vero E6 cells, indicating altered cholesterol distribution, especially in lysosomes, without affecting total cholesterol levels. Among the 28 viral proteins tested, ORF3a showed the strongest increase in filipin puncta, suggesting significant lysosomal cholesterol sequestration.

Notably, SARS-CoV-2 ORF3a localized to lysosomes and caused them to swell, whereas SARS-CoV ORF3a did not induce such effects, highlighting a distinct pathogenic strategy unique to SARS-CoV-2.

ORF3a was found to interact with VPS39, a key component of the HOPS complex involved in cholesterol egress from lysosomes. Key residues W193 and Y184 were shown to form a hydrophobic binding interface critical for this interaction, distinguishing SARS-CoV-2 ORF3a from its SARS-CoV counterpart. Mutations at W193 and Y184 disrupted this interaction, while S171 and H182 had no significant effect.

SARS-CoV-2 ORF3a expression was shown to cause cholesterol accumulation in lysosomes, which was reduced by the W193A mutation. It also led to the mislocalization of NPC2 and increased its secretion, indicating disrupted NPC2 trafficking, likely due to interference with TGN-to-endosome transport. Additionally, BMP levels were significantly reduced in infected cells, which likely exacerbates lysosomal cholesterol sequestration.

In SARS-CoV-2-infected Vero E6 cells, BMP levels were found to decrease at 12 hours post-infection, coinciding with increased cholesterol at 18 hours. In HeLa-Flp-In cells, SARS-CoV-2 ORF3a was found to reduce BMP levels by 20%, with partial rescue in the W193A mutant. Lipidomics confirmed this reduction, correlating BMP loss with cholesterol accumulation and suggesting BMP reduction may contribute to cholesterol sequestration.

SARS-CoV-2 may reduce plasma membrane cholesterol to limit secondary infections, as shown by decreased SARS-CoV-2 infection in NPC1 inhibitor-treated cells. This supports the hypothesis that the virus manipulates cholesterol distribution to optimize replication conditions. Interestingly, the virus also appears to reduce its own infectivity within a single cell, suggesting a self-regulating mechanism to prevent viral overload and ensure broader host-level spread.

Conclusion In conclusion, a novel mechanism by which SARS-CoV-2 disrupts host cell lipid metabolism, specifically through cholesterol sequestration in lysosomes, has been elucidated. By uncovering the specific interaction between the viral protein ORF3a and host protein VPS39, the study highlights a critical role of lysosomal cholesterol trafficking disruption in SARS-CoV-2 pathogenesis.

This discovery opens potential therapeutic avenues to target lipid dysregulation in COVID-19, which could help mitigate both the disease's immediate and long-term metabolic consequences, including dyslipidemia and cardiovascular complications.

Journal reference: Preliminary scientific report. Manipulation of Host Cholesterol by SARS-CoV-2. Aliza Doyle et al., bioRxiv, 2024.11.13.623299 (2024), DOI: 10.1101/2024.11.13.623299,

Study Link: www.biorxiv.org/content/10.1101/2024.11.13.623299v1

[problematicsashawaybright]

Speaking as a weird little freak who listens to people's public conversations, I love being in the campus library at the same time as the Thursday morning nursing major study group because as a psychology major with a focus in psychopharmacology, I only ever understand around 10% of what they're saying, but I listen to that 10% like a dog after you say the word "treat". They're currently having a heated discussion about the use of metformin in hyperglycemia and I don't understand how the pancreas functions, but I do know that they are beginning to use metformin for antipsychotic induced weight gain in patients who develop dyslipidemia due to 2nd gen antipsychs, with around 140 studies having been conducted on patients taking clozapine, olanzapine, and risperidone. However I still do not understand how insulin works.